Logo image of HVT.CA

HARVEST ONE CANNABIS INC (HVT.CA) Stock Fundamental Analysis

TSX-V:HVT - TSX Venture Exchange - CA41755P1053 - Common Stock - Currency: CAD

0.03  -0.01 (-14.29%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to HVT. HVT was compared to 34 industry peers in the Pharmaceuticals industry. HVT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, HVT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HVT has reported negative net income.
HVT.CA Yearly Net Income VS EBIT VS OCF VS FCFHVT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -20M -40M -60M

1.2 Ratios

Industry RankSector Rank
ROA -102.61%
ROE N/A
ROIC 16.15%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HVT.CA Yearly ROA, ROE, ROICHVT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -50 -100 -150 -200 -250

1.3 Margins

Industry RankSector Rank
OM 19.08%
PM (TTM) -161.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HVT.CA Yearly Profit, Operating, Gross MarginsHVT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so HVT is still creating some value.
The number of shares outstanding for HVT has been increased compared to 1 year ago.
Compared to 1 year ago, HVT has a worse debt to assets ratio.
HVT.CA Yearly Shares OutstandingHVT.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M 250M
HVT.CA Yearly Total Debt VS Total AssetsHVT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

HVT has an Altman-Z score of -17.08. This is a bad value and indicates that HVT is not financially healthy and even has some risk of bankruptcy.
HVT has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Altman-Z -17.08
ROIC/WACC1.79
WACC9.03%
HVT.CA Yearly LT Debt VS Equity VS FCFHVT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

HVT has a Current Ratio of 1.02. This is a normal value and indicates that HVT is financially healthy and should not expect problems in meeting its short term obligations.
HVT has a Quick Ratio of 1.02. This is a bad value and indicates that HVT is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.64
HVT.CA Yearly Current Assets VS Current LiabilitesHVT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.44% over the past year.
Looking at the last year, HVT shows a very negative growth in Revenue. The Revenue has decreased by -38.19% in the last year.
The Revenue has been growing by 122.12% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)88.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.45%
Revenue 1Y (TTM)-38.19%
Revenue growth 3Y122.12%
Revenue growth 5YN/A
Sales Q2Q%15.39%

3.2 Future

HVT is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.07% yearly.
Based on estimates for the next years, HVT will show a very strong growth in Revenue. The Revenue will grow by 51.78% on average per year.
EPS Next Y-14.64%
EPS Next 2Y-7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year50.65%
Revenue Next 2Y51.78%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
HVT.CA Yearly Revenue VS EstimatesHVT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
HVT.CA Yearly EPS VS EstimatesHVT.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 -0.02 -0.04 -0.06 -0.08 -0.1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HVT. In the last year negative earnings were reported.
Also next year HVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HVT.CA Price Earnings VS Forward Price EarningsHVT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.14
HVT.CA Per share dataHVT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 -0.04

4.3 Compensation for Growth

HVT's earnings are expected to decrease with -7.07% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.07%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HVT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HARVEST ONE CANNABIS INC

TSX-V:HVT (9/9/2022, 7:00:00 PM)

0.03

-0.01 (-14.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.35%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.58M
Analysts37.5
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.9
P/FCF N/A
P/OCF N/A
P/B 1.38
P/tB N/A
EV/EBITDA 2.14
EPS(TTM)-0.05
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.03
BVpS0.02
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -102.61%
ROE N/A
ROCE N/A
ROIC 16.15%
ROICexc N/A
ROICexgc 38.88%
OM 19.08%
PM (TTM) -161.5%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 0.64
Altman-Z -17.08
F-Score5
WACC9.03%
ROIC/WACC1.79
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.45%
EPS Next Y-14.64%
EPS Next 2Y-7.07%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-38.19%
Revenue growth 3Y122.12%
Revenue growth 5YN/A
Sales Q2Q%15.39%
Revenue Next Year50.65%
Revenue Next 2Y51.78%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A